Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide

[1]  C. Figdor,et al.  Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. , 2010, Anticancer research.

[2]  I. Svane,et al.  Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. , 2010, Cytotherapy.

[3]  P. Tassone,et al.  Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy , 2010, Journal of immunotherapy.

[4]  H. Goossens,et al.  Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties , 2009, Journal of Translational Medicine.

[5]  S. Fujii,et al.  DC therapy induces long‐term NK reactivity to tumors via host DC , 2009, European journal of immunology.

[6]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Dietz,et al.  Clinical Grade OK432-activated Dendritic Cells: In Vitro Characterization and Tracking During Intralymphatic Delivery , 2009, Journal of immunotherapy.

[8]  I. Svane,et al.  Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial , 2008, Journal of immunotherapy.

[9]  S. Endres,et al.  Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. , 2008, Journal of immunological methods.

[10]  R. Perret,et al.  Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? , 2008, Tissue antigens.

[11]  B. Czerniecki,et al.  Reengineering dendritic cell‐based anti‐cancer vaccines , 2008, Immunological reviews.

[12]  J. Rosenberg,et al.  Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. , 2008, Oncology reports.

[13]  P. Kantoff,et al.  Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma , 2007, Journal of immunotherapy.

[14]  B. Kavanagh,et al.  Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides , 2007, Journal of immunotherapy.

[15]  Geraint T. Williams,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer , 2006, PloS one.

[16]  J. Marshall,et al.  Targeted therapy for colorectal cancer. , 2006, Current opinion in investigational drugs.

[17]  M. Taniwaki,et al.  Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy , 2006, Cancer Immunology, Immunotherapy.

[18]  N. Hayashi,et al.  Quick Generation of Fully Mature Dendritic Cells From Monocytes With OK432, Low-Dose Prostanoid, and Interferon-α as Potent Immune Enhancers , 2006, Journal of immunotherapy.

[19]  H. Lyerly,et al.  NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity , 2006, Cancer Immunology, Immunotherapy.

[20]  C. Köhne,et al.  Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells , 2006, Cancer Immunology, Immunotherapy.

[21]  James A. Hutchinson,et al.  Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study , 2004, BJU international.

[22]  J. Whang‐Peng,et al.  Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides , 2004, Clinical Cancer Research.

[23]  地主 将久.  Critical Role of MHC Class I-Related Chain A and B Expression on IFN α-Stimulated Dendritic Cells in NK Cell Activation : Impairment in Chronic Hepatitis C Virus Infection , 2004 .

[24]  A. Khar,et al.  Interleukin‐12 secreted by mature dendritic cells mediates activation of NK cell function , 2004, FEBS letters.

[25]  A. Hamann,et al.  Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? , 2004, Springer Seminars in Immunopathology.

[26]  J. Malvehy,et al.  Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate , 2004, Cancer Immunology, Immunotherapy.

[27]  H. Yamaue,et al.  Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells , 2004, Cancer Immunology, Immunotherapy.

[28]  K. Cederbrant,et al.  A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. , 2003, Toxicology.

[29]  C. Figdor,et al.  Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  N. Cascinelli,et al.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.

[31]  S. Endres,et al.  Mature Dendritic Cells Derived from Human Monocytes Within 48 Hours: A Novel Strategy for Dendritic Cell Differentiation from Blood Precursors1 , 2003, The Journal of Immunology.

[32]  N. Hayashi,et al.  Critical Role of MHC Class I-Related Chain A and B Expression on IFN-α-Stimulated Dendritic Cells in NK Cell Activation: Impairment in Chronic Hepatitis C Virus Infection 1 , 2003, The Journal of Immunology.

[33]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  N. Bhardwaj,et al.  A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. , 2002, Vaccine.

[35]  Angus G. Dalgleish,et al.  Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy , 2002, Cancer Immunology, Immunotherapy.

[36]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[37]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[38]  R. Couch,et al.  Human interleukin-12 enhances interferon-gamma-producing influenza-specific memory CD8+ cytotoxic T lymphocytes. , 1999, The Journal of infectious diseases.

[39]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[40]  M. Feltkamp,et al.  Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. , 1994, Behring Institute Mitteilungen.